Abstract
The osteoporosis pathogenesis is
multifactorial and the immune system has an important role. Free radicals and
the proteins or lipids that become glycated after exposure to sugars that may
be related with bone resorption and inflammation.
It is now recognized that the receptor
activator of NF-κB ligand (RANKL) has a major role at the bone resorbing. The
physiological receptor of the biological activity of RANKL is managed by
osteoprotegerin (OPG). The balance of RANKL and OPG in physiological bone
turnover may control the bone density and pathological conditions. This review aims to provide a short overview
of osteoimmunology in osteoporosis.
Keywords
References
- Yeter A, Kavuncu V, Evcik FD, Demirdal ÜS, Subaşı V, Çakır T. Evalution the effects of raloxifene and risedronate on serum biochemical markers. Türk Osteoporoz derg 2014; 20: 110-116.
- Pietschmann P, Mechtcheriakova D, Meshcheryakova A, Föger-Samwald U, Ellinger I. Immunology of Osteoporosis: A Mini-Review. Gerontology 2016; 62: 128-137.
- Arron JR, Choi Y. Bone versus immune system. Nature 2000; 408: 535-536.
- Rauner M, Sipos W, Thiele S, Pietschmann P. Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities. Int Arch Allergy Immunol 2013; 160: 114-125.
- Blázquez-Medela AM, López-Novoa JM, Martínez-Salgado C. Osteoprotegerin and diabetes-associated pathologies. Curr Mol Med 2011; 5: 401-416.
- Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007; 9(Suppl 1): S1. doi:10.1186/ar2165.
Abstract
References
- Yeter A, Kavuncu V, Evcik FD, Demirdal ÜS, Subaşı V, Çakır T. Evalution the effects of raloxifene and risedronate on serum biochemical markers. Türk Osteoporoz derg 2014; 20: 110-116.
- Pietschmann P, Mechtcheriakova D, Meshcheryakova A, Föger-Samwald U, Ellinger I. Immunology of Osteoporosis: A Mini-Review. Gerontology 2016; 62: 128-137.
- Arron JR, Choi Y. Bone versus immune system. Nature 2000; 408: 535-536.
- Rauner M, Sipos W, Thiele S, Pietschmann P. Advances in osteoimmunology: pathophysiologic concepts and treatment opportunities. Int Arch Allergy Immunol 2013; 160: 114-125.
- Blázquez-Medela AM, López-Novoa JM, Martínez-Salgado C. Osteoprotegerin and diabetes-associated pathologies. Curr Mol Med 2011; 5: 401-416.
- Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007; 9(Suppl 1): S1. doi:10.1186/ar2165.
Details
| Primary Language | English |
|---|---|
| Subjects | Clinical Sciences |
| Journal Section | Review Article |
| Authors | |
| Publication Date | September 30, 2016 |
| Published in Issue | Year 2016 Volume: 1 Issue: 2 |
Cite
Creative Commons Attribution Non-Commercial License: The articles in the Journal of Immunology and Clinical Microbiology are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.